Xoma’s Acquisition Bid Reaches Critical Juncture

The fate of Xoma Royalty’s proposed acquisition of LAVA Therapeutics hangs in the balance as shareholders convene for a decisive vote. The biotechnology firm’s pursuit of its competitor has reached its final stages, with revised terms significantly altering the transaction’s financial dynamics and sending technical signals about Xoma’s stock performance.

During today’s extraordinary general meeting in Amsterdam, LAVA Therapeutics shareholders are determining whether to accept Xoma Royalty’s takeover offer under substantially modified conditions. The per-share cash consideration has been reduced from the original range of $1.16 to $1.24 down to just $1.04. This downward adjustment is partially offset by the introduction of a contingent value right that could Read more...